Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Evaluating Treatments for Amyotrophic Lateral Sclerosis

22:34
 
Share
 

Manage episode 467111522 series 2714709
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content:

  continue reading

854 episodes

Artwork
iconShare
 
Manage episode 467111522 series 2714709
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

The HEALEY ALS platform is an innovative first attempt at platform trials in ALS, looking to slow ALS disease progression. Author Sabrina Paganoni, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses results of the first 4 drug regimens from this platform trial and how this study design makes efficient use of resources, with JAMA Deputy Editor Christopher Muth, MD. Related Content:

  continue reading

854 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play